Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copper Cu 64 PSMA I&T PET/CT for Initial Nodal Staging in High-Risk Prostate Cancer
2024-512754-16-00Phase 3Withdrawn
- Sponsor
- Curium
- Start
- Sep 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of copper Cu 64 PSMA I&T in prostate cancer (PCa), sponsored by Curium. Primary endpoints: Sensitivity of Copper Cu 64 PSMA I&T PET/CT for detection of metastatic pelvic lymph nodes and Specificity of Copper Cu 64 PSMA I&T PET/CT for exclusion of metastatic pelvic lymph nodes. Planned start Sep 2024; status: withdrawn.
02
Drugs
copper Cu 64 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2024-512754-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512754-16-00.